In this article (Clin Cancer Res 2014;20:1576–89), which was published in the March 15, 2014, issue of Clinical Cancer Research (1), there is incorrect wording in a figure title and a figure layout error. The title for Fig. 6 was incorrectly printed as “Figure 6. MLN4924 enhances the activity of BCR signaling inhibitor CAL-101 and alkylating agents in CLL.” It should read as follows: “Figure 6. MLN4924 enhances the activity of BCR signaling inhibitors in CLL.” The authors regret this error. In Fig. 3A, the label “CLL49” was mistakenly placed inside the image. The corrected version of Fig. 3 is below. The publisher regrets this error. The conclusions put forth in the article remain unchanged and unaffected by these errors.
- ©2016 American Association for Cancer Research.